KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Shares Outstanding (2016 - 2025)

Pacira BioSciences has reported Shares Outstanding over the past 16 years, most recently at $41.1 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $41.1 million for Q4 2025, down 11.08% from a year ago — trailing twelve months through Dec 2025 was $41.1 million (down 11.08% YoY), and the annual figure for FY2025 was $41.1 million, down 11.08%.
  • Shares Outstanding for Q4 2025 was $41.1 million at Pacira BioSciences, down from $47.7 million in the prior quarter.
  • Over the last five years, Shares Outstanding for PCRX hit a ceiling of $47.7 million in Q3 2025 and a floor of $41.1 million in Q4 2025.
  • Median Shares Outstanding over the past 5 years was $46.2 million (2023), compared with a mean of $45.8 million.
  • Biggest five-year swings in Shares Outstanding: increased 4.37% in 2021 and later fell 11.08% in 2025.
  • Pacira BioSciences' Shares Outstanding stood at $44.7 million in 2021, then increased by 2.67% to $45.9 million in 2022, then grew by 1.2% to $46.5 million in 2023, then dropped by 0.52% to $46.2 million in 2024, then fell by 11.08% to $41.1 million in 2025.
  • The last three reported values for Shares Outstanding were $41.1 million (Q4 2025), $43.0 million (Q3 2025), and $47.7 million (Q2 2025) per Business Quant data.